{"id":52665,"date":"2026-03-17T13:26:19","date_gmt":"2026-03-17T07:56:19","guid":{"rendered":"https:\/\/shekhawatisamachar.com\/index.php\/2026\/03\/17\/new-therapies-bring-new-hope-for-lymphoma-patients-dr-rahul-bhargava\/"},"modified":"2026-03-17T13:26:19","modified_gmt":"2026-03-17T07:56:19","slug":"new-therapies-bring-new-hope-for-lymphoma-patients-dr-rahul-bhargava","status":"publish","type":"post","link":"https:\/\/shekhawatisamachar.com\/index.php\/2026\/03\/17\/new-therapies-bring-new-hope-for-lymphoma-patients-dr-rahul-bhargava\/","title":{"rendered":"New Therapies Bring New Hope for Lymphoma Patients: Dr. Rahul Bhargava"},"content":{"rendered":"<p><strong>New Delhi [India], March 17:<\/strong> Recent advances in cancer treatment are transforming the outlook for patients with lymphoma, offering renewed hope where options were once limited. According to Dr. Rahul Bhargava, one of India\u2019s leading hematologists and stem cell transplant specialists, newer treatments such as CAR-T cell therapy and BiTE (Bispecific T-cell Engager) therapy are redefining outcomes for patients with relapsed or refractory lymphoma.<\/p>\n<p>\u201cFor decades, lymphoma treatment relied largely on chemotherapy, monoclonal antibodies, and targeted therapies,\u201d says Dr. Bhargava. \u201cThese treatments helped control the disease and extended life expectancy for many patients. However, nearly 40% of patients would still experience relapse despite receiving the best available therapies, leaving them with limited treatment options.\u201d<\/p>\n<p>According to data from clinical trials and real-world studies in the United States, CAR-T cell therapy has shown remarkable results in lymphoma patients who have already failed multiple prior treatments. Studies have reported overall response rates ranging from 50% to 80%, with complete remission achieved in about 40% to 54% of patients in relapsed or refractory disease settings.<\/p>\n<p>\u201cCAR-T therapy represents a paradigm shift,\u201d explains Dr. Bhargava. \u201cInstead of repeatedly suppressing the cancer, we engineer the patient\u2019s own immune cells to recognize and destroy lymphoma cells. In many patients this can lead to durable remission, and in some cases it may even provide a cure.\u201d<\/p>\n<p>Another promising innovation is BiTE therapy, a class of bispecific antibodies designed to bring immune T-cells directly into contact with cancer cells, enabling the immune system to destroy malignant lymphocytes with precision.<\/p>\n<p>\u201cBiTE therapy is particularly exciting because it can also be used as a long-term maintenance strategy,\u201d says Dr. Bhargava. \u201cPatients may remain on this therapy for extended periods, sometimes for many years, helping keep the disease under control while maintaining a good quality of life.\u201d<\/p>\n<p>Dr. Bhargava recalls the case of Rohit (name changed), a 42-year-old professional from Delhi, who was diagnosed with aggressive lymphoma four years ago. After initial chemotherapy and targeted therapies, his disease relapsed.<\/p>\n<p>\u201cWhen Rohit came to us, he had already undergone multiple treatments and the lymphoma had returned,\u201d Dr. Bhargava recounts. \u201cWe evaluated him for advanced cellular therapy and proceeded with CAR-T cell treatment.\u201d<\/p>\n<p>Within weeks, Rohit began showing a remarkable response. Follow-up scans showed significant regression of the disease, and over time the lymphoma completely disappeared. Today, he remains disease-free and has returned to his normal work and family life.<\/p>\n<p>\u201cStories like Rohit\u2019s highlight how far lymphoma treatment has progressed,\u201d says Dr. Bhargava. \u201cPatients who previously had very limited options can now achieve long-term remission and potentially a cure.\u201d<\/p>\n<p>Dr. Bhargava also notes that India has been able to adopt these cutting-edge therapies relatively early.<\/p>\n<p>\u201cDue to the proactive approach of the Indian government under the leadership of Prime Minister Narendra Modi , Indian patients have been able to gain access to advanced treatments such as CAR-T cell therapy much earlier than many expected,\u201d he says. \u201cThis is a significant step forward in ensuring that patients in India benefit from the latest breakthroughs in cancer treatment.\u201d<\/p>\n<p><em>If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi [India], March 17: Recent advances in cancer treatment are transforming the outlook for patients with lymphoma, offering renewed hope where options were once limited. According to Dr. Rahul Bhargava, one of India\u2019s leading hematologists and stem cell transplant specialists, newer treatments such as CAR-T cell therapy and BiTE (Bispecific T-cell Engager) therapy are [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":52664,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[51,5],"tags":[2839],"class_list":["post-52665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-press-release","tag-lymphoma"],"_links":{"self":[{"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/posts\/52665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/comments?post=52665"}],"version-history":[{"count":0,"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/posts\/52665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/media\/52664"}],"wp:attachment":[{"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/media?parent=52665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/categories?post=52665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/shekhawatisamachar.com\/index.php\/wp-json\/wp\/v2\/tags?post=52665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}